palivizumab sold brand name synagis monoclonal antibody produced recombinant dna technology used prevent severe disease caused respiratory syncytial virus rsv recommended infants highrisk rsv due conditions prematurity medical problems including heart lung common side effects include fever palivizumab humanized monoclonal antibody igg directed epitope antigenic site f protein rsv two phase iii clinical trials pediatric population palivizumab reduced risk hospitalization due rsv infection palivizumab dosed month via intramuscular im injection administered throughout duration rsv season based past trends started midseptember palivizumab targets fusion protein inhibiting entry cell thereby preventing infection palivizumab approved medical use palivizumab indicated prevention serious lower respiratory tract disease requiring hospitalization caused respiratory syncytial virus rsv children high risk rsv american academy pediatrics published guidelines use palivizumab recent updates recommendations based new information regarding rsv seasonality palivizumab pharmacokinetics incidence bronchiolitis hospitalizations effect gestational age risk factors rsv hospitalization rates mortality children hospitalized rsv infection effect prophylaxis wheezing palivizumabresistant rsv infants younger one year born weeks ie weeks days gestation recommended use palivizumab infants younger one year bronchopulmonary dysplasia ie born weeks gestation required supplemental oxygen first days birth infants younger two years bronchopulmonary dysplasia require medical therapy eg supplemental oxygen glucocorticoids diuretics within six months anticipated rsv season recommended use palivizumab taking palivizumab prophylactically decreases number rsv infections decreases wheezing may decrease rate hospitalization attributed negative side effects clear palivizumab effective safe medical conditions put higher risk serious cases rsv deficiencies immune since risk rsv decreases first year following birth use palivizumab children months age generally recommended exception premature infants need supplemental oxygen bronchodilator therapy steroid therapy time second rsv decisions regarding palivizumab prophylaxis children groups made casebycase palivizumab passive antibody ineffective treatment rsv infection administration recommended updated cochrane review found differences palivizumab placebo outcomes mortality length hospital stay adverse events infants children aged years old larger rcts required palivizumab recommended treatment infant rsv infection despite use palivizumab rsv season monthly doses palivizumab may discontinued rest rsv season due low risk current studies progress determine new treatments rsv rather solely prophylaxis contraindications use palivizumab include hypersensitivity reactions upon exposure palivizumab serious cases anaphylaxis reported exposure palivizumab signs hypersensitivity include hives shortness breath hypotension unresponsiveness contraindications palivizumab studies needed determine drugdrug interactions exist none conducted yet palivizumab use may cause side effects include limited serious side effects include palivizumab demonstrated significantly higher affinity potency neutralizing b subtypes rsv compared treatment mgkg palivizumab led serum concentration Î¼gml cotton rats reduced rsv titers palivizumab monoclonal antibody targets fusion f glycoprotein surface rsv deactivates f protein membrane protein responsible fusing virus target cell highly conserved among subgroups rsv deactivating f protein prevents virus fusing targets cell membrane prevents virus entering host metaanalysis found palivizumab absorption quicker pediatric population compared adults ka vs ka intramuscular bioavailability drug approximately healthy young current recommendation rsv immunoprophylaxis administration x mgkg doses palivizumab maintain body concentrations volume distribution approximately palivizumab drug clearance cl approximately mlday halflife drug approximately days three doses sustaining body concentrations last entire rsv season months metaanalysis estimated clearance pediatric population considering maturation cl body weight showed significant reduction compared palivizumab relatively expensive medication vial ranging multiple studies done manufacturer independent researchers determine costeffectiveness palivizumab found conflicting results heterogeneity studies makes difficult compare given consensus costeffectiveness palivizumab usage largely depends location care individual risk metaanalysis reported palivizumab prophylaxis dominant strategy incremental costeffectiveness ratio per qualityadjusted lifeyear qaly also showed incremental costeffectiveness ratio preterm infants per qaly payer however previously stated costeffectiveness palivizumab undecided metaanalysis one example society benefit palivizumab prophylaxis disease burden rsv young infants global prevalence prompted attempts vaccine development approved vaccine rsv formalininactivated rsv vaccine firsv studied immunized children exposed virus community developed enhanced form rsv disease presented wheezing fever bronchopneumonia enhanced form disease led hospitalization recipients firsv compared control group additionally fatalities occurred among vaccine recipients upon reinfection subsequent subsequent attempts develop attenuated live virus vaccine optimal immune response minimal reactogenicity research animal subjects suggested intravenously administered immunoglobulin high rsv neutralizing activity protect rsv us food drug administration fda approved use respigam rsvigiv prevention serious lower respiratory tract infection caused rsv children younger months age bronchopulmonary dysplasia history premature success rsvigiv demonstrated efficacy immunoprophylaxis prompted research technologies thus palivizumab developed antibody found fifty times potent predecessor antibody widely used rsv since palivizumab originally known developed rsv immune prophylaxis tool easier administer effective current tools time developed period medimmune inc combining human mouse specifically antibody production stimulated mouse model following immunization rsv antibodyproducing b cells isolated mouses spleen fused mouse myeloma cell lines antibodies humanized cloning sequencing dna heavy light chains monoclonal antibody overall monoclonal antibody similar human antibodies dna origins original httpsenwikipediaorgwikipalivizumab